What's Driving the Bearish Options Activity in Eli Lilly

Key Takeaways

• Recent options activity for Eli Lilly (LLY) shows a conspicuous bearish tilt, with 42% of unusual trades favoring puts, despite strong underlying fundamentals.
• Eli Lilly's robust growth is fueled by its GLP-1 drugs, Mounjaro and Zepbound, which accounted for 56% of 2025 revenues, but faces intense competition and manufacturing scale challenges.
• While analysts maintain a strong "Buy" consensus with an average price target of $1214.28, the stock's high valuation metrics suggest future growth is already heavily priced in.

What's Driving the Bearish Options Activity in Eli Lilly?

Recent options market activity for Eli Lilly (LLY) has shown a notable bearish sentiment, a curious development given the company's otherwise strong performance. On March 4, 26 unusual options trades were detected, with 42% of these exhibiting bearish tendencies, compared to just 30% bullish. Specifically, there were 7 put options valued at $289,934 and 19 call options totaling $956,746. While the raw value of calls exceeded puts, the net institutional options flow revealed a bearish sentiment of over $1.6 million below parity, indicating that larger, more sophisticated investors are leaning negative.

This bearish positioning, often referred to as "smart money" flow, suggests that some institutional players might be hedging existing long positions, taking profits after a significant run, or anticipating a short-term correction. The options activity points to a predicted price range for LLY between $740.0 and $1080.0 over the next three months. Eli Lilly's stock is currently trading at $1002.97, down -0.47% today, sitting within this projected range but closer to the higher end. The overall put/call ratio of 0.86 from these specific trades, while seemingly bullish at first glance, is overshadowed by the larger net bearish sentiment in institutional block trades.

It's crucial to interpret unusual options activity not as a definitive forecast, but as a signal of potential shifts in short-term sentiment or strategic hedging. The high volume of options, with total options volume reaching 54,014 contracts recently—a 29.74% lift over the trailing one-month average—underscores increased speculative interest. This heightened activity, particularly the bearish tilt from institutional players, warrants a closer look at the underlying factors that might be influencing such a contrarian view amidst a generally positive narrative for Eli Lilly.

Is Eli Lilly's Recent Pullback a Buying Opportunity or a Warning Sign?

Eli Lilly's stock has experienced some near-term volatility, with shares pulling back about 4% last week following its Q4 earnings report and a further 2% decline over the past month and three months. This recent softness, with the stock trading at $1002.97, comes after a powerful 42% rally from August 2025 to February 2026. For long-term investors, this might appear as a minor blip, especially considering the stock's impressive +18.6% total shareholder return over the past year and a staggering +424.5% over five years.

The current price action suggests a period of profit-taking after a significant run-up, rather than a fundamental deterioration in the company's outlook. Technical indicators, such as the Relative Strength Index (RSI), are reportedly approaching oversold territory, which could signal a potential bounce if the selling pressure eases. However, some market analysts are observing a "6-4-D" sequence in LLY's price action over the past two months—six up weeks, four down weeks, with a negative trajectory across the 10-week period. This pattern, while compressing magnitude, can offer insights into conditional probabilities for future price movements.

While a "6-4-D" sequence might suggest a negative short-term trajectory, historical data indicates that LLY stock typically enjoys a strong upward bias, with a 60.18% chance of a profitable long position in any given week. When this specific sequence flashes, the probability of upside in the following week increases to 68.42%, with a median return of 2.47%. This suggests that despite the recent bearish options activity and price pullback, the statistical probabilities still lean towards a bullish outcome in the immediate future. Therefore, for investors with a long-term horizon, the current dip could indeed present a strategic entry point, provided the underlying fundamentals remain robust.

How Strong Are Eli Lilly's Growth Engines?

Eli Lilly's growth narrative is overwhelmingly dominated by its blockbuster GLP-1 therapies, Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). These dual GIP and GLP-1 receptor agonists have been nothing short of transformative for the company, driving an exceptional surge in revenues. In 2025, Mounjaro and Zepbound collectively generated $36.5 billion in sales, accounting for a remarkable 56% of Eli Lilly's total revenues. Analysts project Mounjaro sales to grow from $18.4 billion in 2025 to $22.8 billion in 2026, while Zepbound is expected to jump from $4.9 billion in 2024 to $12.5 billion in 2025 and an impressive $18.1 billion in 2026.

Beyond these two powerhouses, Eli Lilly is actively diversifying its portfolio with other newly approved therapies, including Omvoh, Jaypirca, Ebglyss, and Kisunla, which are also contributing to revenue growth. The company's trailing twelve-month (TTM) financial fundamentals underscore this robust performance: revenue reached $72.58 billion, up 44.7% year-over-year. Net income soared by 94.9%, and EPS saw a staggering 96.0% increase. Free Cash Flow (FCF) growth was particularly explosive, rising by 2065.6% year-over-year.

Looking ahead, Eli Lilly's 2026 outlook is equally optimistic, with revenue guidance set between $80 billion and $83 billion, and non-GAAP EPS projected to be between $33.50 and $35.00. The company's operating margins have expanded significantly to 45.6%, reflecting strong operating leverage despite heavy investments in manufacturing capacity and R&D. This combination of dominant market-leading products, a promising pipeline, and exceptional financial metrics paints a picture of a company with powerful and accelerating growth engines.

What Are the Key Risks and Competitive Headwinds for LLY?

Despite Eli Lilly's stellar performance, the company faces several significant risks and competitive headwinds that warrant investor attention. The most immediate challenge is the intense competition in the burgeoning GLP-1 market. While Lilly's Mounjaro and Zepbound are market leaders, Novo Nordisk's Ozempic and Wegovy are formidable rivals. Novo Nordisk has already gained a first-to-market advantage with its oral Wegovy, launched in January 2026, potentially impacting Lilly's market share until its own oral GLP-1, orforglipron, launches in Q2 2026 in the US.

Beyond direct competition, the core investment debate centers on Lilly's ability to scale manufacturing fast enough to meet insatiable GLP-1 demand without compromising quality, while simultaneously defending prices against increasing payer and political pressure. Declining net prices for many of Lilly’s products in the U.S. are a reality, expected to be a drag on top-line growth in the low to mid-teens percentage in 2026. Furthermore, sales of late-life cycle products like Trulicity, Taltz, and Verzenio are anticipated to be flat or even decline in 2026, placing even greater reliance on the GLP-1 franchise.

The company's high valuation also presents a risk. Trading at a P/E of 43.64, P/S of 14.52, and EV/EBITDA of 35.14, LLY is significantly more expensive than its pharmaceutical peers. While justified by its exceptional growth, any slowdown in GLP-1 sales, intensified competition, or unexpected pipeline setbacks could lead to a sharp re-evaluation. Concerns over GLP-1 safety, or if high monthly pricing and new competitors like Structure Therapeutics and Viking Therapeutics start to squeeze demand, could significantly impact the company's growth narrative and valuation.

How Should Investors Interpret LLY's Valuation and Analyst Sentiment?

Eli Lilly's current valuation metrics are undeniably stretched, reflecting the market's enthusiastic pricing of its future growth potential, particularly from its GLP-1 franchise. The stock trades at a P/E ratio of 43.64, a P/S ratio of 14.52, and an EV/EBITDA of 35.14. These figures are considerably higher than industry averages, suggesting that much of the anticipated growth is already baked into the current share price of $1002.97. The TTM earnings yield stands at a modest 2.3%, and the FCF yield is even lower at 0.9%, indicating that investors are paying a premium for future cash flows.

Despite the high valuation, Wall Street analysts maintain a overwhelmingly bullish stance on LLY. Out of 44 analysts, 32 rate it a "Buy" and 10 a "Hold", with only 2 "Sell" ratings. The consensus price target is $1214.28, with a median of $1255.00 and a high of $1350.00. This implies a potential upside of around 21% from the current price to the consensus target. Recent ratings, such as Deutsche Bank maintaining a "Buy" with a $1285.00 target and Cantor Fitzgerald maintaining "Overweight" with a $1205.00 target, reinforce this positive sentiment.

The divergence between the cautious options activity and the strong analyst consensus highlights the complexity of LLY's investment profile. Analysts are largely focused on the long-term growth trajectory driven by Mounjaro, Zepbound, and the promising pipeline, including orforglipron and retatrutide. Their models often assume robust revenue growth (CAGR of 17.9% through 2028) and expanding operating margins (48.9%). For investors, this means balancing the undeniable growth catalysts with the elevated valuation and the short-term bearish signals from options traders. A long-term perspective focused on pipeline execution and market penetration remains key, but vigilance regarding competitive dynamics and manufacturing scale is essential.

Eli Lilly presents a compelling, albeit complex, investment case. Its GLP-1 drugs are undeniable game-changers, driving exceptional financial performance and a robust pipeline promises continued innovation. However, the stock's premium valuation and recent bearish options activity signal that investors must carefully weigh growth prospects against competitive pressures and execution risks. For those with a long-term horizon, LLY remains a strong contender, but short-term volatility should be anticipated.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.